Alb-cre+/MYC+
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Strain Description
Alb-Cre+/MYC+ mice are generated by crossing H11-CAG-LSL-hMYC-IRES-EGFP mice (Catalog Number: C001338), which conditionally express the human c-Myc oncogene, with Alb-Cre mice that express Cre recombinase specifically in hepatocytes under the control of the Alb promoter. The Cre-mediated recombination results in the deletion of the transcriptional stop sequence (Loxp-Stop-Loxp, LSL) in H11-CAG-LSL-hMYC-IRES-EGFP mice, leading to overexpression of the MYC oncogene in the liver and subsequent carcinogenesis. This model, therefore, spontaneously develops liver cancer with an early onset.
Application Area
Liver Cancer Research: The model overexpresses the MYC oncogene in the liver, spontaneously developing liver cancer, thus serving as a tool to study the mechanisms of liver cancer initiation and progression
Drug Screening and Evaluation: Utilized to assess the efficacy of new anti-liver cancer drugs and therapeutic strategies, particularly those targeting MYC-driven tumors
Gene Function Studies: Investigates the role of the MYC gene in hepatocytes and its involvement in tumor formation
Transcriptional Regulation Studies: Explores the mechanisms of MYC in transcriptional regulation and its interactions with other genes and signaling pathways
Detailed Information